3 mRNA-based COVID-19 vaccine developers under the spotlight

BioNTech, CureVac and Moderna have probably benefited the most from the pandemic. Publicity aside, shareholders risked a lot of capital prior to the pandemic, with uncertain outcomes. All companies have shown great clinical success so far, but which one used its capital most efficiently?

BioNTech, CureVac and Moderna have raised staggering USD 8.7bn from private and public capital markets so far and a total market capitalization of USD 102.4bn.

Moderna rewards its shareholders by returning 15x on the capital employed, followed by BioNTech (11x) and CureVac (7x).

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here:

[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]